It’s déjà vu for digital health, with yet another record-breaking half. The continued upward trajectory from 2017 through the first half of 2018 is not a fluke. Instead, this sustained growth is indicative of the maturation one would expect from a stable, emerging investment sector (coupled with a strong overall venture ecosystem). Read on to learn our five key findings from this eventful half.
While the Enterprise Insights Forum is invite-only, some tidbits were too good not to share. In our latest podcast episode, we recount the opening session of the day with Professor and Chair of the Department of Medicine at UCSF, Dr. Bob Wachter, and Google Ventures partner and physician-scientist Dr. Vineeta Agarwala exploring what algorithms will do for healthcare—and when. Read on for five key themes and takeaways from two of the day’s sessions about enterprise adoption of AI-driven innovation.
Do you know someone with a chronic illness, disease, or injury whose health experience has been impacted by technology? Their voices are integral to the conversations we have at Rock Health Summit. This year, we’re excited and honored to offer a handful of nominees complimentary passes and an opportunity to speak at the event. Nominate someone you know (or yourself) to attend.
As one of the last industries to undergo technological transformation on an exponential scale, healthcare is ripe for change—and attracting the attention of diverse industries like never before. What opportunities do transportation, finance, food, and other companies see in healthcare? What trends are leading non-traditional companies into this balkanized industry? And what lessons should healthcare learn from them?
Over 100 digital health CEOs joined us last month at the sixth annual Digital Health CEO Summit, co-hosted with Penn Wharton Entrepreneurship, BioQuest, and Match Point Partners. The Summit provided startup CEOs with a space for candid conversations about the challenges and triumphs of building a digital health company. They discussed what it means for digital health to be maturing as a sector, the challenge of simultaneously building products and testing new business models within an evolving industry, and what it takes to make this job sustainable—and enjoyable.
On the heels of the biggest year in venture funding, the digital health space is starting off 2018 with a bang: record Q1 funding of $1.62B, three $100M+ mega-deals, and a massive exit. Compared to last year, the commotion from policy debates has largely settled and a path to regulatory clarity has emerged. On our end, we’ve launched a couple of new sections within our funding post—check out our deep investor analysis as well as an update on the sometimes elusive, always critical quest of every digital health company: validation.
After seven years, we’ve seen $23B invested into thousands of digital health companies. But we wanted to know: what has been the real-world impact of digital health? We were moved to learn just how many lives had been significantly changed by a new wave of technology. We aim to shift the digital health dialogue from one focused on the degree of investment and future expectations to one about digital health’s effect on patients and healthcare outcomes. In that spirit, this ongoing project brings you stories of people living far outside Silicon Valley and the companies shifting the healthcare status quo who have made an impact on their lives.
AI in healthcare feels inevitable: Optimists predict that artificial intelligence and machine learning (AI/ML) will diagnose disease better and earlier, treat illness more precisely, and engage patients more efficiently than today’s healthcare system does. On top of this, AI/ML is expected to streamline business operations and restore sanity (and humanity) to the clinician experience. To separate hype from reality, read our 50-page white paper, Demystifying AI and Machine Learning in Healthcare.
Even small med device, drug, or digital health companies can shell out hundreds of thousands of dollars annually in consulting fees on labor-intensive, slow, paper-based processes—with larger companies spending millions. These companies are tackling some of healthcare’s biggest problems, and we believe regulatory compliance workflow shouldn’t be an expensive bottleneck. That’s why we’re thrilled to announce our latest investment in Enzyme, a company building software to help large and small enterprises alike streamline workflow, making regulatory compliance a seamless part of the development process.